Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 1,387 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 1,387 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.04, for a total value of $16,699.48. Following the completion of the sale, the chief financial officer now owns 71,832 shares of the company’s stock, valued at $864,857.28. The sale was disclosed in a filing with the SEC, which is available at this link.

Houte Hans Van also recently made the following trade(s):

• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $68,256.24.

Nurix Therapeutics Stock Up 8.8 %

NRIX opened at $13.08 on Thursday. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $18.12. The firm’s fifty day moving average price is $13.76 and its 200 day moving average price is $9.86.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The company had revenue of $15.16 million during the quarter, compared to analyst estimates of $30.66 million. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 351.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares during the last quarter. Quest Partners LLC bought a new stake in Nurix Therapeutics during the fourth quarter valued at $59,000. Principal Financial Group Inc. raised its holdings in shares of Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock worth $122,000 after purchasing an additional 2,002 shares during the period. Jump Financial LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $158,000. Finally, SG Americas Securities LLC acquired a new position in shares of Nurix Therapeutics in the 3rd quarter valued at about $162,000.

Wall Street Analyst Weigh In

Several research firms recently commented on NRIX. Morgan Stanley boosted their price target on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Royal Bank of Canada upped their target price on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Wells Fargo & Company dropped their price target on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, February 16th. Needham & Company LLC reissued a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. Finally, Robert W. Baird lifted their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.